Amidst a cautious market environment shaped by RBA rate hikes and global tech volatility, a closer look reveals resilient opportunities. We examine three ASX-listed penny stocks—from biotech to mining—that are navigating the headwinds with distinct strategies and potential.
Bitcoin fell below $73,000 on Feb. 4, 2026, reaching its lowest level since April 2025 and triggering a double-digit selloff in major mining stocks. The decline extends a four-month retreat from all-time highs, pressured by large holder sales and waning mining profitability.
Beyond the spotlight on Nvidia and ChatGPT, the AI infrastructure rush is creating a historic surge for memory and storage chipmakers, with stock gains eclipsing 1,000% as supply struggles to meet explosive data center demand.
Figma shares have tumbled sharply, caught in a broader sell-off of design software stocks fueled by analyst pessimism and mounting concerns over AI's disruptive potential. The sell-off raises questions about whether the market is overreacting or correctly pricing in new competitive risks.
As the TSX rides a wave of positive earnings momentum, investors are sifting through smaller-cap names for growth potential. We examine three companies—spanning crypto, energy, and digital assets—that are catching the eye of analysts, despite the inherent risks of the 'penny stock' category.
As Amazon prepares to report its fourth-quarter results, strong performance across its core businesses is expected. Yet, despite solid fundamentals, the stock has languished, leaving investors to weigh near-term AI costs against long-term growth potential.
CNBC's Jim Cramer acknowledged Moderna's strong January performance but expressed caution, noting the company faces years of unprofitability and highlighting other pharmaceutical and biotech stocks he finds more attractive for investment.
Argan's shares have skyrocketed, closing at $381.73 after a 194% annual surge. However, a deep dive into valuation metrics suggests the stock may be significantly overvalued, raising questions about its current risk-reward profile for investors.
Shares of regional lender TriCo Bancshares (TCBK) have posted strong gains over the past quarter, outpacing broader bank indices. This momentum has ignited a fresh debate among analysts and investors: Is the stock still a value play, or has the market run ahead of itself?
Amphenol's shares have delivered stellar multi-year returns, leaving investors to question if the connectivity giant is still a buy. A deep dive into valuation metrics reveals a stock trading near fair value, but with significant optimism already priced in.
Shares of thermal management specialist Modine Manufacturing have more than doubled over the past year, fueled by data center cooling demand. As the stock trades near record highs, investors are weighing whether its premium valuation is justified by future growth prospects.
After years of impressive gains, CBRE Group's stock faces scrutiny. A deep dive into valuation metrics suggests the market may be pricing in excessive optimism, raising questions about future returns for investors.
AppLovin's shares have faced significant pressure recently, declining roughly 25% over the past month and year-to-date. This slump contrasts sharply with its stellar long-term returns and blockbuster Q3 earnings, leaving investors to debate whether the stock is now undervalued or if growth concerns are justified.
Coinbase expands its automated threat intelligence sharing via Crypto ISAC, aiming to bolster ecosystem defenses against sophisticated cyber threats, including state-sponsored actors. The security push unfolds against a backdrop of significant volatility in the company's stock price.
Despite a 9% stock surge over the past quarter, Richelieu Hardware (TSE:RCH) presents a complex financial picture. While its Return on Equity aligns with the industry average, a persistent decline in net income and puzzling growth dynamics raise questions about the sustainability of its recent gains, even as analysts forecast a potential turnaround.
Amid a buoyant start to 2026 for major U.S. indices, investor attention is turning to smaller-cap opportunities. We examine three penny stocks—spanning AI, event tech, and nuclear medicine—that are navigating unique growth paths, acquisitions, and challenges in the current economic climate.
As major indexes flirt with record highs, investors are turning to dividend-paying stocks for income and ballast. We examine three companies offering yields up to 4.8% and a history of reliable payouts.
A sharp sell-off in semiconductor and AI infrastructure stocks pressured the Nasdaq to a two-week low, offsetting gains in the Dow. The rotation follows mixed corporate earnings and signals a potential cooling of the recent tech frenzy.
After years of steady but modest expansion, Johnson & Johnson projects a significant acceleration in revenue, driven by a bold ambition to dominate the global oncology market. With shares trading at a premium, analysts debate if the stock's future growth potential justifies its current price.
Japanese pharmaceutical giant Shionogi reports robust nine-month results, driving a significant share price surge. As the stock trades above some analyst targets yet below intrinsic value estimates, investors are weighing whether the momentum has run its course or if there's still room to grow.
